PROBLEM TO BE SOLVED: To provide peptides, nucleic acids, and cells for use in immunotherapeutic methods against cancers including gastrointestinal cancer and gastric cancer.SOLUTION: A method is used in cancer therapy, the method using peptide epitopes of tumor-associated impaired T cell (CTL) alone or using these epitopes in combination with other tumor-associated proteins acting as pharmaceutical active components of vaccine compositions stimulating anti-tumor immune responses. A fusion peptide is included, the peptide comprising 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. The peptide comprises a specific amino acid sequence or a sequence thereof having a length of 8 to 100 amino acids, 8 to 30 amino acids, or 8 to 14 amino acids. The fusion peptide comprises a N-terminal amino acid of HLA-DR antigen-related mutant chain (Ii) and the above peptide.SELECTED DRAWING: None【課題】消化管癌及び胃癌を含む癌に対する、免疫療法で用いられるペプチド、核酸及び細胞の提供。【解決手段】癌の免疫療法における、更に、腫瘍関連障害性T細胞（CTL）のペプチドエピトープ単独について、あるいは抗腫瘍免疫応答を刺激するワクチン組成物の薬剤有効成分として働く他の腫瘍関連ペプチドとこれらエピトープとの組み合わせ方法。抗腫瘍免疫応答を誘発するワクチン組成物で使用され得る、ヒト腫瘍細胞のHLAクラスI分子に由来する95個の新規ペプチド配列と変異体を含む融合ペプチドを含む。特定のアミノ酸配列を含むペプチド又はその配列であって、全長が８～１００アミノ酸長、８～３０アミノ酸長又は８～１４アミノ酸長であるペプチド。ＨＬＡ－ＤＲ抗原関連変異体鎖（Ｉｉ）のＮ末端アミノ酸及び前記ペプチドを含む融合ペプチド。【選択図】なし
